20250519_OMED_Laporan Informasi dan Fakta Material_31886734_lamp3.pdf

                         INFORMATION TO SHAREHOLDERS
PT Jayamas Medica Industri Tbk (“the Company”) plans to carry out a buyback of its issued shares
listed on the Indonesia Stock Exchange, referring to the Financial Services Authority Regulation
No. 13/POJK.04/2023 concerning Policies to Maintain Performance and Market Stability under
Significantly Fluctuating Market Conditions, and OJK Letter No. S-17/D.04/2025 dated March 18, 2025,
regarding the Policy on the Implementation of Share Buybacks by Public Companies under Significantly
Fluctuating Market Conditions.

The total value of the Buyback is estimated at a maximum of IDR 10,000,000,000 (ten billion Rupiah).

The implementation of the Buyback will take into account the Company's liquidity and capital conditions,
as well as the provisions of applicable laws and regulations. The Company will not conduct a Buyback
if it will result in a reduction in the number of shares at a certain level that can significantly reduce the
liquidity of shares on the Stock Exchange.

                                   INDICATIVE TIMETABLE
Indicative Timetable

Information Disclosure regarding the share buyback                            : 19 May 2025
Share buyback period                                                          : 20 May – 20 August 2025

    ESTIMATE OF BUYBACK EXPENSES AND NOMINAL VALUE OF
                   ALL BUYBACK SHARES
The Buyback is planned to be a maximum of IDR10,000,000,000 (ten billion Rupiah) from the
Company's internal cash. The funds include all expenses that will be incurred by the Company in
implementing the Buyback during the period of May 20, 2025 to August 20, 2025, which include
transaction costs, intermediary trading costs, and other related costs in connection with the Buyback
transaction.

In accordance with Article 2 paragraph (1) of POJK 29/2023 in conjunction with Article 37 paragraph
(1) of Law No. 40 of 2007 concerning Limited Liability Companies, the number of shares to be bought
back will not exceed 10% (ten percent) of the total paid-up capital.

In carrying out this Buyback, the Company will continue to pay attention to the number of free float
shares that must be fulfilled by the Company in accordance with the provisions of applicable laws and
regulations.

  PROJECTION OF REDUCED EARNINGS OF THE COMPANY AS A
  RESULT OF THE REPURCHASING OF COMPANY SHARES AND
             IMPACT TO COMPANY’S FINANCING
According to the results of the Company's internal analysis, the implementation of the Buyback will not
have a significant negative impact on the Company's performance and income because the Company's
current profit balance and cash flow are sufficient to meet the funding requirements to implement the
Buyback.




                                                      2

            PERFORMANCE OF COMPANY’S EARNINGS PER SHARE AFTER
                           THE SHARES BUYBACK
         The following is the proforma earnings per share of the Company based on the Company’s financial
         statements for the period ending March 31th, 2025, taking into account the value of the maximum share
         buyback of IDR10,000,000,000.-


                                                                 As of March 31th, 2025 (in millions of Rupiah)
                     Description                                Before the                             After the
                                                                Shares            Effect               Shares
                                                                Buyback                                Buyback
Total Asset                                                        2,936,534             10,000            2,926,534
Total Equity                                                       2,568,776             10,000            2,558,776
Net Profit for the Year Attributable to Owners of the                  72,764                                  72,764
Parent Entity
Earnings per Share                                                       2.69                                    2.69

              RESTRICTION TO SHARE PRICE FOR THE SHARES BUYBACK
         The buyback will be carried out at a price considered good and reasonable by the Company's
         management by taking into account the provisions of Articles 11 and 12 of POJK 29/2023.

                  LIMITATION TO THE PERIOD OF THE SHARES BUYBACK
         The share buyback will be carried out within a period of three (3) months following the date of the
         Disclosure of Information, namely from May 20th to August 20th 2025.

                      METHOD IMPLEMENTED IN THE SHARES BUYBACK
         The Company will carry out the Buyback with the following provisions:

             1. The Company's share repurchase will be conducted through the Indonesia Stock Exchange
                (Bursa Efek Indonesia), and therefore, the share purchase transactions of the Company will be
                executed through one of the Exchange Members, namely PT RHB Sekuritas Indonesia;
             2. The volume of Buyback to be carried out by the Company in 1 (one) trading day is not limited.

           DISCUSSION AND MANAGEMENT ANALYSIS ON THE IMPACT OF
               THE SHARES BUYBACK TO THE COMPANY’S FUTURE
                          ACTIVITIES AND GROWTH
         The Company's revenue is not expected to decrease due to the implementation of the Buyback.

             1. Buyback does not have a significant impact on the Company's operations;
             2. The Company believes that the implementation of the Buyback will not have a material negative
                impact on the Company's business activities and growth, because the Company currently has
                sufficient capital and cash flow to carry out and finance all business activities, business
                development activities, operational activities and the Buyback.




                                                           3

              SOURCE OF FUNDS FOR THE SHARES BUYBACK
The source of funding for the Buyback comes from the Company's internal cash. This source of funding
has met the provisions of Article 5 of POJK 29/2023, namely:

    1.   does not significantly affect the Company's financial ability to meet maturing obligations;
    2.   using the Company's internal funds;
    3.   not funds resulting from a public offering; and
    4.   not funds originating from loans and/or debts in any form.


                                   OTHER INFORMATION
Treasury shares do not have voting rights and are not taken into account in determining the quorum at
the GMS, and are not entitled to dividends.

Referring to the provisions of Article 43 of POJK 29/2023, the parties are:
   a) members of the board of commissioners, members of the board of directors, employees and
        major shareholders of the Company;
   b) an individual who, due to his position or profession or because of his business relationship with
        the Company, is able to obtain inside information;
   c) a party who within the last 6 (six) months is no longer a party as referred to in letter (a) or letter
        (b).

prohibited from carrying out transactions on the Company's shares on the same day as the Buyback
or sale of shares resulting from the Buyback carried out by the Company through the Stock Exchange.

                               ADDITIONAL INFORMATION
For the Company's shareholders who require more detailed information regarding this Information
Disclosure, the Company's Shareholders may submit it to the Company's Corporate Secretary and
Investor Relations, on any working day and during the Company's working hours at the address below:

                                             Kantor Pusat:
                                      By Pass Krian Ds. Sidomojo
                                  Krian Sidoarjo, Jawa Timur 61262
                               Telp: (0231) 898 2349 / (0231) 898 5268
                                      Website: http://onemed.co.id
                               Email: corporate.secretary@onemed.co.id




                                                     4